The event: FDA approval decision for Adcetris in two cancers -- relapsed or refractory Hodgkin's lymphoma, and relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
The timeline: The FDA approval decision is expected Aug. 30. Before that, on July 14, the FDA is convening an FDA advisory panel to review Adcetris.
The stakes: Seattle Genetics carries a market value of $2.4 billion, which means investors have not only banked on Adcetris' approval but are also expecting the drug to perform well commercially. Two important firsts hinge on Adcetris: It will be the first approved drug to emerge from Seattle Genetics' lab; and the first drug to validate the company's antibody drug conjugate technology. Adcetris combines the tumor-targeting precision of a monoclonal antibody with the tumor-killing power of chemotherapy.